Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mirm-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 millio
Peetz Christopher (CHIEF EXECUTIVE OFFICER) sold 20,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $122.27 ($121.65–$124.79, $2.45M total) across 4 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
BJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 5,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $122.25 ($121.67–$124.94, $0.61M total) across 4 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
Over the past 7 days, alphai's AI scored 1 news story mentioning MIRM (Mirum Pharmaceuticals, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent MIRM coverage spans insider activity, earnings and corporate actions.
In the last 30 days, MIRM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($194K). The most active reporter was Howe Jolanda, SVP, GLOBAL CONTROLLER, with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Guidance increase plus new FDA designations and a revised volixibat NDA timeline (H1 2027) are likely to re-rate near-term probability of regulatory progress.
This is an insider open-market sale under a 10b5-1 plan, which typically has limited signal value for near-term fundamentals.
This is a routine, pre-arranged insider sale disclosure, not a new operational or financial catalyst.
This is a routine corporate governance 8-K with no new operating/financial guidance, but it confirms shareholder support for the board and executive compensation.
Clinical readouts improve probability of near-term regulatory filings (NDA H2 2026; BLA 2027) and de-risk development timelines.
alphai scores every news story that mentions MIRM with an AI model for sentiment and relevance, and aggregates insider trades from Mirum Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Mirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 mirm-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update – Q2 2026 net product sales of $176 million – 2026 net product sales guidance increased to $680 million to $700 millio
6 min readPeetz Christopher (CHIEF EXECUTIVE OFFICER) sold 20,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $122.27 ($121.65–$124.79, $2.45M total) across 4 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
1 min readBJERKHOLT ERIC (CHIEF FINANCIAL OFFICER) sold 5,000 shares of Mirum Pharmaceuticals, Inc. (MIRM) at an average of $122.25 ($121.67–$124.94, $0.61M total) across 4 trades on 2026-07-06 under a Rule 10b5-1 trading plan.
1 min readMirum Pharmaceuticals, Inc. (MIRM) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001759425 0001759425 2026-06-15 2026-06-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15,
2 min readMirum Pharmaceuticals reported Phase 2b results at the EASL Congress. In VISTAS, volixibat in primary sclerosing cholangitis reduced pruritus and the company plans an NDA submission in H2 2026. In AZURE-1, brelovitug in chronic hepatitis delta virus showed virologic response and ALT normalization at Week 24; Phase 3 topline data are expected later in 2026.
4 min readThe article is largely promotional and does not provide verifiable details of Mirum Pharmaceuticals’ Phase 2b results for volixibat in PSC. It references an “EASL Congress” update but includes no specific efficacy/safety figures. It also promotes subscription offers and claims about prior stock-pick performance and “upside potential,” without citing sources.
6 min readPeetz Christopher (CHIEF EXECUTIVE OFFICER) sold 883 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $99.66 on 2026-06-01 under a Rule 10b5-1 trading plan.
3 min readPeetz Christopher (CHIEF EXECUTIVE OFFICER) sold 1,021 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $98.20 ($0.10M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
1 min readPeetz Christopher (CHIEF EXECUTIVE OFFICER) sold 1,973 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $97.56 ($0.19M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min readPeetz Christopher (CHIEF EXECUTIVE OFFICER) sold 6,926 shares of Mirum Pharmaceuticals, Inc. (MIRM) at $96.15 ($0.67M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
2 min read
